IL1B and neoplasm: As anakinra is able to cross the blood–brain barrier and reaches therapeutically relevant concentration within the central nervous system [52,53,54], pharmacological interruption of tumor-associated inflammation by antagonizing IL-1 signaling might be an interesting new strategy by which to ameliorate GBM aggressiveness.